Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants: A Meta-Analysis
{{output}}
Importance: Nirsevimab, a long-acting monoclonal antibody available since 2023, has demonstrated effectiveness in preventing lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) in clinical trials ... ...
